{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:17:16Z","timestamp":1793236636326,"version":"4.5.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100016220","name":"Georgia Clinical and Translational Science Alliance","doi-asserted-by":"publisher","award":["UL1 TR002378"],"award-info":[{"award-number":["UL1 TR002378"]}],"id":[{"id":"10.13039\/100016220","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH NCI","award":["K12 CA237806"],"award-info":[{"award-number":["K12 CA237806"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1245\/s10434-023-14712-9","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T19:02:12Z","timestamp":1701975732000},"page":"1509-1518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Management of Gastric Neuroendocrine Tumors: A Review"],"prefix":"10.1245","volume":"31","author":[{"given":"Caitlin","family":"Sok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranay S.","family":"Ajay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Tsagkalidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Kooby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4665-5534","authenticated-orcid":false,"given":"Mihir M.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"issue":"3","key":"14712_CR1","first-page":"338","volume":"90","author":"CJ Gilligan","year":"1995","unstructured":"Gilligan CJ, Lawton GP, Tang LH, West AB, Modlin IM. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol. 1995;90(3):338\u201352.","journal-title":"Am J Gastroenterol."},{"issue":"4","key":"14712_CR2","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/0016-5085(93)90266-f","volume":"104","author":"G Rindi","year":"1993","unstructured":"Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology. 1993;104(4):994\u20131006. https:\/\/doi.org\/10.1016\/0016-5085(93)90266-f.","journal-title":"Gastroenterology."},{"key":"14712_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33210","author":"MK Washington","year":"2020","unstructured":"Washington MK, Goldberg RM, Chang GJ, et al. Diagnosis of digestive system tumours. Int J Cancer. 2020. https:\/\/doi.org\/10.1002\/ijc.33210.","journal-title":"Int J Cancer."},{"key":"14712_CR4","unstructured":"Klimstra DS KG, La Rosa S, Rindi G. Classification of neuroendocrine neoplasms of the digestive system, 5th edn. WHO classification of tumours: Digestive system tumours. International Agency for Research on Cancer; 2019."},{"issue":"2","key":"14712_CR5","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO;2-4","volume":"36","author":"JD Godwin 2nd","year":"1975","unstructured":"Godwin JD 2nd. Carcinoid tumors. An analysis of 2837 cases. Cancer. 1975;36(2):560\u20139.","journal-title":"Cancer."},{"issue":"3","key":"14712_CR6","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s12020-017-1355-9","volume":"57","author":"S Manfredi","year":"2017","unstructured":"Manfredi S, Walter T, Baudin E, et al. Management of gastric neuro-endocrine tumours in a large French national cohort (GTE). Endocrine. 2017;57(3):504\u201311. https:\/\/doi.org\/10.1007\/s12020-017-1355-9.","journal-title":"Endocrine."},{"issue":"4","key":"14712_CR7","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10120-020-01046-8","volume":"23","author":"P Hu","year":"2020","unstructured":"Hu P, Bai J, Liu M, et al. Trends of incidence and prognosis of gastric neuroendocrine neoplasms: a study based on SEER and our multicenter research. Gastric Cancer. 2020;23(4):591\u20139. https:\/\/doi.org\/10.1007\/s10120-020-01046-8.","journal-title":"Gastric Cancer."},{"issue":"2","key":"14712_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1530\/eje-12-0836","volume":"168","author":"D Thomas","year":"2013","unstructured":"Thomas D, Tsolakis AV, Grozinsky-Glasberg S, et al. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur J Endocrinol. 2013;168(2):185\u201393. https:\/\/doi.org\/10.1530\/eje-12-0836.","journal-title":"Eur J Endocrinol."},{"issue":"8","key":"14712_CR9","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s00268-011-1137-0","volume":"35","author":"L Zhang","year":"2011","unstructured":"Zhang L, Ozao J, Warner R, Divino C. Review of the pathogenesis, diagnosis, and management of type I gastric carcinoid tumor. World J Surg. 2011;35(8):1879\u201386. https:\/\/doi.org\/10.1007\/s00268-011-1137-0.","journal-title":"World J Surg."},{"key":"14712_CR10","doi-asserted-by":"publisher","first-page":"8273","DOI":"10.2147\/cmar.S334171","volume":"13","author":"X Liu","year":"2021","unstructured":"Liu X, Zhang Z, Huang J, Tan H, Yang Z. Efficacy and safety of interferon-alpha 2b for patients with hepatic epithelioid hemangioendothelioma: outcomes of a case-series analysis. Cancer Manag Res. 2021;13:8273\u20139. https:\/\/doi.org\/10.2147\/cmar.S334171.","journal-title":"Cancer Manag Res."},{"key":"14712_CR11","unstructured":"NCCN. National Comprehensive Cancer Network-Neuroendocrine and Adrenal Tumors. Accessed 10 Dec 2020, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/neuroendocrine.pdf"},{"issue":"8","key":"14712_CR12","doi-asserted-by":"publisher","first-page":"850","DOI":"10.4251\/wjgo.v12.i8.850","volume":"12","author":"GA Roberto","year":"2020","unstructured":"Roberto GA, Rodrigues CMB, Peixoto RD, Younes RN. Gastric neuroendocrine tumor: a practical literature review. World J Gastrointest Oncol. 2020;12(8):850\u20136. https:\/\/doi.org\/10.4251\/wjgo.v12.i8.850.","journal-title":"World J Gastrointest Oncol."},{"issue":"2","key":"14712_CR13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s002689900026","volume":"20","author":"G Rindi","year":"1996","unstructured":"Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg. 1996;20(2):168\u201372. https:\/\/doi.org\/10.1007\/s002689900026.","journal-title":"World J Surg."},{"issue":"1","key":"14712_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1001\/archsurg.136.1.49","volume":"136","author":"M Schindl","year":"2001","unstructured":"Schindl M, Kaserer K, Niederle B. Treatment of gastric neuroendocrine tumors: the necessity of a type-adapted treatment. Arch Surg. 2001;136(1):49\u201354. https:\/\/doi.org\/10.1001\/archsurg.136.1.49.","journal-title":"Arch Surg."},{"issue":"7","key":"14712_CR15","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3109\/00365528809090760","volume":"23","author":"SM Sjoblom","year":"1988","unstructured":"Sjoblom SM. Clinical presentation and prognosis of gastrointestinal carcinoid tumours. Scand J Gastroenterol. 1988;23(7):779\u201387. https:\/\/doi.org\/10.3109\/00365528809090760.","journal-title":"Scand J Gastroenterol."},{"issue":"5","key":"14712_CR16","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.amjsurg.2018.12.057","volume":"217","author":"A Crown","year":"2019","unstructured":"Crown A, Kennecke H, Kozarek R, et al. Gastric carcinoids: Does type of surgery or tumor affect survival? Am J Surg. 2019;217(5):937\u201342. https:\/\/doi.org\/10.1016\/j.amjsurg.2018.12.057.","journal-title":"Am J Surg."},{"key":"14712_CR17","volume-title":"World Health Organization classification of tumours\u2014pathology and genetics of tumours of the digestive system","author":"ES Capella","year":"2000","unstructured":"Capella ES, Sobin LH, Arnold R. Endocrine tumours of the stomach. In: World Health Organization classification of tumours\u2014pathology and genetics of tumours of the digestive system. IARCPress; 2000."},{"issue":"2\u20133","key":"14712_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000369275","volume":"100","author":"ML van Velthuysen","year":"2014","unstructured":"van Velthuysen ML, Groen EJ, van der Noort V, van de Pol A, Tesselaar ME, Korse CM. Grading of neuroendocrine neoplasms: mitoses and Ki-67 are both essential. Neuroendocrinology. 2014;100(2\u20133):221\u20137. https:\/\/doi.org\/10.1159\/000369275.","journal-title":"Neuroendocrinology."},{"issue":"10","key":"14712_CR19","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1634\/theoncologist.2015-0476","volume":"21","author":"R Coriat","year":"2016","unstructured":"Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P. Gastroenteropancreatic well-differentiated grade 3 neuroendocrine tumors: review and position statement. Oncologist. 2016;21(10):1191\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2015-0476.","journal-title":"Oncologist."},{"issue":"2","key":"14712_CR20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","volume":"76","author":"ID Nagtegaal","year":"2020","unstructured":"Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182\u20138. https:\/\/doi.org\/10.1111\/his.13975.","journal-title":"Histopathology."},{"key":"14712_CR21","volume-title":"AJCC Cancer Staging Manual","year":"2017","unstructured":"Amin MBES, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, et al editors. AJCC Cancer Staging Manual. 8th edn. American Joint Commission on Cancer: Springer International Publishing; 2017.","edition":"8"},{"issue":"12","key":"14712_CR22","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/j.1365-2036.2011.04659.x","volume":"33","author":"L Vannella","year":"2011","unstructured":"Vannella L, Sbrozzi-Vanni A, Lahner E, et al. Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther. 2011;33(12):1361\u20139. https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04659.x.","journal-title":"Aliment Pharmacol Ther."},{"issue":"12","key":"14712_CR23","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1097\/00042737-200112000-00008","volume":"13","author":"B Annibale","year":"2001","unstructured":"Annibale B, Azzoni C, Corleto VD, et al. Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid. Eur J Gastroenterol Hepatol. 2001;13(12):1449\u201356. https:\/\/doi.org\/10.1097\/00042737-200112000-00008.","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"6","key":"14712_CR24","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/s0016-5085(99)70495-6","volume":"116","author":"AD Higham","year":"1999","unstructured":"Higham AD, Bishop LA, Dimaline R, et al. Mutations of RegIalpha are associated with enterochromaffin-like cell tumor development in patients with hypergastrinemia. Gastroenterology. 1999;116(6):1310\u20138. https:\/\/doi.org\/10.1016\/s0016-5085(99)70495-6.","journal-title":"Gastroenterology."},{"issue":"1","key":"14712_CR25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3748\/wjg.v20.i1.118","volume":"20","author":"TT Li","year":"2014","unstructured":"Li TT, Qiu F, Qian ZR, Wan J, Qi XK, Wu BY. Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors. World J Gastroenterol. 2014;20(1):118\u201325. https:\/\/doi.org\/10.3748\/wjg.v20.i1.118.","journal-title":"World J Gastroenterol."},{"issue":"1","key":"14712_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/s1470-2045(07)70410-2","volume":"9","author":"IM Modlin","year":"2008","unstructured":"Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61\u201372. https:\/\/doi.org\/10.1016\/s1470-2045(07)70410-2.","journal-title":"Lancet Oncol."},{"issue":"6","key":"14712_CR27","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1097\/MPA.0b013e3181ebb168","volume":"39","author":"MH Kulke","year":"2010","unstructured":"Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39(6):735\u201352. https:\/\/doi.org\/10.1097\/MPA.0b013e3181ebb168.","journal-title":"Pancreas."},{"issue":"Suppl 3","key":"14712_CR28","first-page":"9","volume":"10","author":"JB Cwikla","year":"2004","unstructured":"Cwikla JB, Buscombe JR, Caplin ME, et al. Diagnostic imaging of carcinoid metastases to the abdomen and pelvis. Med Sci Monit. 2004;10(Suppl 3):9\u201316.","journal-title":"Med Sci Monit."},{"issue":"1","key":"14712_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1530\/eje.0.1510015","volume":"151","author":"G Kaltsas","year":"2004","unstructured":"Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol. 2004;151(1):15\u201327. https:\/\/doi.org\/10.1530\/eje.0.1510015.","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"14712_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000443168","volume":"103","author":"G Delle Fave","year":"2016","unstructured":"Delle Fave G, O\u2019Toole D, Sundin A, et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):119\u201324. https:\/\/doi.org\/10.1159\/000443168.","journal-title":"Neuroendocrinology."},{"issue":"2","key":"14712_CR31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000335595","volume":"95","author":"G Delle Fave","year":"2012","unstructured":"Delle Fave G, Kwekkeboom DJ, Van Cutsem E, et al. ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology. 2012;95(2):74\u201387. https:\/\/doi.org\/10.1159\/000335595.","journal-title":"Neuroendocrinology."},{"issue":"1","key":"14712_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000510962","volume":"38","author":"JL Chin","year":"2021","unstructured":"Chin JL, O\u2019Connell J, Muldoon C, et al. Selective resection of type 1 gastric neuroendocrine neoplasms and the risk of progression in an endoscopic surveillance programme. Dig Surg. 2021;38(1):38\u201345. https:\/\/doi.org\/10.1159\/000510962.","journal-title":"Dig Surg."},{"issue":"4","key":"14712_CR33","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/cen.14055","volume":"91","author":"K Daskalakis","year":"2019","unstructured":"Daskalakis K, Tsoli M, Karapanagioti A, et al. Recurrence and metastatic potential in type 1 gastric neuroendocrine neoplasms. Clin Endocrinol. 2019;91(4):534\u201343. https:\/\/doi.org\/10.1111\/cen.14055.","journal-title":"Clin Endocrinol."},{"issue":"1","key":"14712_CR34","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12876-021-01821-6","volume":"21","author":"GR Sivandzadeh","year":"2021","unstructured":"Sivandzadeh GR, Ejtehadi F, Shoaee S, et al. Endoscopic mucosal resection: still a reliable therapeutic option for gastrointestinal neuroendocrine tumors. BMC Gastroenterol. 2021;21(1):238. https:\/\/doi.org\/10.1186\/s12876-021-01821-6.","journal-title":"BMC Gastroenterol."},{"issue":"6","key":"14712_CR35","doi-asserted-by":"publisher","first-page":"E717","DOI":"10.1055\/a-1119-6698","volume":"8","author":"F Hawa","year":"2020","unstructured":"Hawa F, Sako Z, Nguyen T, et al. The band and slough technique is effective for management of diminutive type 1 gastric and duodenal neuroendocrine tumors. Endosc Int Open. 2020;8(6):E717\u201321. https:\/\/doi.org\/10.1055\/a-1119-6698.","journal-title":"Endosc Int Open."},{"issue":"126","key":"14712_CR36","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.5754\/hge121185","volume":"60","author":"Y Sato","year":"2013","unstructured":"Sato Y, Takeuchi M, Hashimoto S, et al. Usefulness of endoscopic submucosal dissection for type I gastric carcinoid tumors compared with endoscopic mucosal resection. Hepatogastroenterology. 2013;60(126):1524\u20139. https:\/\/doi.org\/10.5754\/hge121185.","journal-title":"Hepatogastroenterology."},{"issue":"2","key":"14712_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11938-007-0064-5","volume":"10","author":"W Hou","year":"2007","unstructured":"Hou W, Schubert ML. Treatment of gastric carcinoids. Curr Treat Options Gastroenterol. 2007;10(2):123\u201333. https:\/\/doi.org\/10.1007\/s11938-007-0064-5.","journal-title":"Curr Treat Options Gastroenterol."},{"key":"14712_CR38","unstructured":"Kulke MH SM, Benson AB, Bergsland E, Berlin JD, Besh SA et al. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Neuroendocrine Tumors Version 2; 2018. https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/neuroendocrine.pdf. 2018"},{"issue":"4","key":"14712_CR39","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.amjsurg.2015.08.040","volume":"211","author":"HE Jenny","year":"2016","unstructured":"Jenny HE, Ogando PA, Fujitani K, Warner RR, Divino CM. Laparoscopic antrectomy: a safe and definitive treatment in managing type 1 gastric carcinoids. Am J Surg. 2016;211(4):778\u201382. https:\/\/doi.org\/10.1016\/j.amjsurg.2015.08.040.","journal-title":"Am J Surg."},{"issue":"1","key":"14712_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40792-021-01109-7","volume":"7","author":"J Kitadani","year":"2021","unstructured":"Kitadani J, Ojima T, Hayata K, et al. Single-incision laparoscopic antrectomy for type I gastric neuroendocrine tumor: a case report. Surg Case Rep. 2021;7(1):15. https:\/\/doi.org\/10.1186\/s40792-021-01109-7.","journal-title":"Surg Case Rep."},{"issue":"1","key":"14712_CR41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jss.2010.01.005","volume":"162","author":"J Ozao-Choy","year":"2010","unstructured":"Ozao-Choy J, Buch K, Strauchen JA, Warner RR, Divino CM. Laparoscopic antrectomy for the treatment of type I gastric carcinoid tumors. J Surg Res. 2010;162(1):22\u20135. https:\/\/doi.org\/10.1016\/j.jss.2010.01.005.","journal-title":"J Surg Res."},{"issue":"1","key":"14712_CR42","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/01.sla.0000167862.52309.7d","volume":"242","author":"K Borch","year":"2005","unstructured":"Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg. 2005;242(1):64\u201373. https:\/\/doi.org\/10.1097\/01.sla.0000167862.52309.7d.","journal-title":"Ann Surg."},{"issue":"11","key":"14712_CR43","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1245\/s10434-009-0687-y","volume":"16","author":"RA Gladdy","year":"2009","unstructured":"Gladdy RA, Strong VE, Coit D, et al. Defining surgical indications for type I gastric carcinoid tumor. Ann Surg Oncol. 2009;16(11):3154. https:\/\/doi.org\/10.1245\/s10434-009-0687-y.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"14712_CR44","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1677\/erc-07-0251","volume":"15","author":"D Campana","year":"2008","unstructured":"Campana D, Nori F, Pezzilli R, et al. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer. 2008;15(1):337\u201342. https:\/\/doi.org\/10.1677\/erc-07-0251.","journal-title":"Endocr Relat Cancer."},{"issue":"10","key":"14712_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076462","volume":"8","author":"AR Moore","year":"2013","unstructured":"Moore AR, Boyce M, Steele IA, Campbell F, Varro A, Pritchard DM. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS One. 2013;8(10):e76462. https:\/\/doi.org\/10.1371\/journal.pone.0076462.","journal-title":"PLoS One."},{"issue":"11\u201312","key":"14712_CR46","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/apt.12090","volume":"36","author":"R Fossmark","year":"2012","unstructured":"Fossmark R, S\u00f8rdal \u00d8, Jianu CS, et al. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther. 2012;36(11\u201312):1067\u201375. https:\/\/doi.org\/10.1111\/apt.12090.","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"14712_CR47","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1053\/gast.2002.34231","volume":"123","author":"PL Peghini","year":"2002","unstructured":"Peghini PL, Annibale B, Azzoni C, et al. Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology. 2002;123(1):68\u201385. https:\/\/doi.org\/10.1053\/gast.2002.34231.","journal-title":"Gastroenterology."},{"issue":"9","key":"14712_CR48","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/j.1365-2036.2006.03130.x","volume":"24","author":"MD Burkitt","year":"2006","unstructured":"Burkitt MD, Pritchard DM. Review article: pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther. 2006;24(9):1305\u201320. https:\/\/doi.org\/10.1111\/j.1365-2036.2006.03130.x.","journal-title":"Aliment Pharmacol Ther."},{"issue":"35","key":"14712_CR49","doi-asserted-by":"publisher","first-page":"5890","DOI":"10.3748\/wjg.v27.i35.5890","volume":"27","author":"RE Rossi","year":"2021","unstructured":"Rossi RE, Elvevi A, Citterio D, et al. Gastrinoma and Zollinger Ellison syndrome: a roadmap for the management between new and old therapies. World J Gastroenterol. 2021;27(35):5890\u2013907. https:\/\/doi.org\/10.3748\/wjg.v27.i35.5890.","journal-title":"World J Gastroenterol."},{"issue":"11","key":"14712_CR50","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/RLU.0000000000002276","volume":"43","author":"S Singh","year":"2018","unstructured":"Singh S, Poon R, Wong R, Metser U. 68Ga PET imaging in patients with neuroendocrine tumors: a systematic review and meta-analysis. Clin Nucl Med. 2018;43(11):802\u201310. https:\/\/doi.org\/10.1097\/RLU.0000000000002276.","journal-title":"Clin Nucl Med."},{"key":"14712_CR51","unstructured":"Giusti F, Marini F, Brandi ML. Multiple endocrine neoplasia type 1. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews((R)). 1993."},{"key":"14712_CR52","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaa031","author":"ML Brandi","year":"2020","unstructured":"Brandi ML, Agarwal SK, Perrier ND, Lines KE, Valk GD, Thakker RV. Multiple endocrine neoplasia type 1: latest insights. Endocr Rev. 2020. https:\/\/doi.org\/10.1210\/endrev\/bnaa031.","journal-title":"Endocr Rev."},{"key":"14712_CR53","unstructured":"Cingam SR, Botejue M, Hoilat GJ, Karanchi H. Gastrinoma. StatPearls. 2023."},{"issue":"3","key":"14712_CR54","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/gastro\/gov004","volume":"3","author":"S Dacha","year":"2015","unstructured":"Dacha S, Razvi M, Massaad J, Cai Q, Wehbi M. Hypergastrinemia. Gastroenterol Rep (Oxf). 2015;3(3):201\u20138. https:\/\/doi.org\/10.1093\/gastro\/gov004.","journal-title":"Gastroenterol Rep (Oxf)."},{"issue":"16","key":"14712_CR55","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1200\/JCO.2014.60.2532","volume":"33","author":"PL Kunz","year":"2015","unstructured":"Kunz PL. Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol. 2015;33(16):1855\u201363. https:\/\/doi.org\/10.1200\/JCO.2014.60.2532.","journal-title":"J Clin Oncol."},{"issue":"10","key":"14712_CR56","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/apt.12698","volume":"39","author":"R Basuroy","year":"2014","unstructured":"Basuroy R, Srirajaskanthan R, Prachalias A, Quaglia A, Ramage JK. Review article: the investigation and management of gastric neuroendocrine tumours. Aliment Pharmacol Ther. 2014;39(10):1071\u201384. https:\/\/doi.org\/10.1111\/apt.12698.","journal-title":"Aliment Pharmacol Ther."},{"issue":"11","key":"14712_CR57","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/bjs.10901","volume":"105","author":"BH Min","year":"2018","unstructured":"Min BH, Hong M, Lee JH, et al. Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours. Br J Surg. 2018;105(11):1480\u20136. https:\/\/doi.org\/10.1002\/bjs.10901.","journal-title":"Br J Surg."},{"issue":"46","key":"14712_CR58","doi-asserted-by":"publisher","first-page":"8703","DOI":"10.3748\/wjg.v19.i46.8703","volume":"19","author":"YH Kwon","year":"2013","unstructured":"Kwon YH, Jeon SW, Kim GH, et al. Long-term follow up of endoscopic resection for type 3 gastric NET. World J Gastroenterol. 2013;19(46):8703\u20138. https:\/\/doi.org\/10.3748\/wjg.v19.i46.8703.","journal-title":"World J Gastroenterol."},{"issue":"13","key":"14712_CR59","doi-asserted-by":"publisher","first-page":"8838","DOI":"10.1245\/s10434-021-10293-7","volume":"28","author":"A Hanna","year":"2021","unstructured":"Hanna A, Kim-Kiselak C, Tang R, et al. Gastric neuroendocrine tumors: reappraisal of type in predicting outcome. Ann Surg Oncol. 2021;28(13):8838\u201346. https:\/\/doi.org\/10.1245\/s10434-021-10293-7.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"14712_CR60","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12957-022-02625-y","volume":"20","author":"K Iwasaki","year":"2022","unstructured":"Iwasaki K, Barroga E, Enomoto M, et al. Long-term surgical outcomes of gastric neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasms. World J Surg Oncol. 2022;20(1):165. https:\/\/doi.org\/10.1186\/s12957-022-02625-y.","journal-title":"World J Surg Oncol."},{"key":"14712_CR61","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-22-0206","author":"JR Eads","year":"2023","unstructured":"Eads JR, Halfdanarson TR, Asmis T, et al. expert consensus practice recommendations of the North American neuroendocrine tumor society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Endocr Relat Cancer. 2023. https:\/\/doi.org\/10.1530\/ERC-22-0206.","journal-title":"Endocr Relat Cancer."},{"issue":"8","key":"14712_CR62","doi-asserted-by":"publisher","first-page":"791","DOI":"10.4251\/wjgo.v12.i8.791","volume":"12","author":"M Ahmed","year":"2020","unstructured":"Ahmed M. Gastrointestinal neuroendocrine tumors in 2020. World J Gastrointest Oncol. 2020;12(8):791\u2013807. https:\/\/doi.org\/10.4251\/wjgo.v12.i8.791.","journal-title":"World J Gastrointest Oncol."},{"key":"14712_CR63","doi-asserted-by":"crossref","unstructured":"Travis W, Brambilla E, Burke A, Marx A, Nicholson A. WHO classification of tumours of the lung, pleura, thymus and heart. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 2015.","DOI":"10.1097\/JTO.0000000000000663"},{"key":"14712_CR64","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rinde","year":"2022","unstructured":"Rinde G, Mete O, Uccella S, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33:115\u201354.","journal-title":"Endocr Pathol."},{"key":"14712_CR65","doi-asserted-by":"publisher","first-page":"W260","DOI":"10.2214\/AJR.13.11310","volume":"203","author":"S Feng","year":"2014","unstructured":"Feng S, Luo Y, Chan T, et al. CT evaluation of gastroenteric neuroendocrine tumors: relationship between CT features and the pathologic classification. AJR Am J Roentgenol. 2014;203:W260\u20136.","journal-title":"AJR Am J Roentgenol."},{"issue":"1","key":"14712_CR66","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cpet.2013.08.008","volume":"9","author":"E Panagiotidis","year":"2014","unstructured":"Panagiotidis E, Bomanji J. Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors. PET Clin. 2014;9(1):43\u201355. https:\/\/doi.org\/10.1016\/j.cpet.2013.08.008.","journal-title":"PET Clin."},{"issue":"2","key":"14712_CR67","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.surg.2014.09.011","volume":"157","author":"Y Tomimaru","year":"2015","unstructured":"Tomimaru Y, Eguchi H, Tatsumi M, et al. Clinical utility of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors. Surgery. 2015;157(2):269\u201376. https:\/\/doi.org\/10.1016\/j.surg.2014.09.011.","journal-title":"Surgery."},{"issue":"1","key":"14712_CR68","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13550-019-0585-7","volume":"9","author":"S Majala","year":"2019","unstructured":"Majala S, Seppanen H, Kemppainen J, et al. Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET\/CT. EJNMMI Res. 2019;9(1):116. https:\/\/doi.org\/10.1186\/s13550-019-0585-7.","journal-title":"EJNMMI Res."},{"issue":"7","key":"14712_CR69","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1634\/theoncologist.2018-0382","volume":"24","author":"OB Alese","year":"2019","unstructured":"Alese OB, Jiang R, Shaib W, et al. High-grade gastrointestinal neuroendocrine carcinoma management and outcomes: a national cancer database study. Oncologist. 2019;24(7):911\u201320. https:\/\/doi.org\/10.1634\/theoncologist.2018-0382.","journal-title":"Oncologist."},{"key":"14712_CR70","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12885-015-1999-x","volume":"16","author":"J Akimoto","year":"2016","unstructured":"Akimoto J, Fukuhara H, Suda T, et al. Clinicopathological analysis in patients with neuroendocrine tumors that metastasized to the brain. BMC Cancer. 2016;16:36. https:\/\/doi.org\/10.1186\/s12885-015-1999-x.","journal-title":"BMC Cancer."},{"key":"14712_CR71","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/oncolo\/oyab039","volume":"27","author":"A Dasari","year":"2022","unstructured":"Dasari A, Shen C, Devabhaktuni A, Nighot R, Sorbye H. Survival according to primary tumor location, stage, and treatment patterns in locoregional gastroenteropancreatic high-grade neuroendocrine carcinomas. Oncologist. 2022;27:299\u2013306.","journal-title":"Oncologist."},{"key":"14712_CR72","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/onco.13686","volume":"26","author":"A Liu","year":"2021","unstructured":"Liu A, Ueberroth B, McGarrah P, et al. Treatment outcomes of well-differentiated high-grade neuroendocrine tumors. Oncologist. 2021;26:383\u20138.","journal-title":"Oncologist."},{"key":"14712_CR73","doi-asserted-by":"publisher","first-page":"e12967","DOI":"10.1111\/jne.12967","volume":"33","author":"H Pommergaard","year":"2021","unstructured":"Pommergaard H, Nielsen K, Sorbye H, et al. Surgery of the primary tumor in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms. J Neuroendocrinol. 2021;33:e12967.","journal-title":"J Neuroendocrinol."},{"key":"14712_CR74","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1158\/1078-0432.CCR-15-0548","volume":"22","author":"L Tang","year":"2016","unstructured":"Tang L, Untch B, Reidy D, et al. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin Cancer Res. 2016;22:1011\u20137.","journal-title":"Clin Cancer Res."},{"issue":"6","key":"14712_CR75","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.surg.2021.01.026","volume":"169","author":"LW Thornblade","year":"2021","unstructured":"Thornblade LW, Warner SG, Melstrom L, et al. Does surgery provide a survival advantage in non-disseminated poorly differentiated gastroenteropancreatic neuroendocrine neoplasms? Surgery. 2021;169(6):1417\u201323. https:\/\/doi.org\/10.1016\/j.surg.2021.01.026.","journal-title":"Surgery."},{"issue":"3","key":"14712_CR76","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13249","volume":"35","author":"H Sorbye","year":"2023","unstructured":"Sorbye H, Grande E, Pavel M, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. J Neuroendocrinol. 2023;35(3):e13249. https:\/\/doi.org\/10.1111\/jne.13249.","journal-title":"J Neuroendocrinol."},{"issue":"1","key":"14712_CR77","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1053\/j.seminoncol.2012.11.011","volume":"40","author":"J Smith","year":"2013","unstructured":"Smith J, Reidy-Lagunes D. The management of extrapulmonary poorly differentiated (high-grade) neuroendocrine carcinomas. Semin Oncol. 2013;40(1):100\u20138. https:\/\/doi.org\/10.1053\/j.seminoncol.2012.11.011.","journal-title":"Semin Oncol."},{"issue":"7","key":"14712_CR78","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, Oberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844\u201360. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.304.","journal-title":"Ann Oncol."},{"issue":"2","key":"14712_CR79","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000443172","volume":"103","author":"R Garcia-Carbonero","year":"2016","unstructured":"Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS Consensus Guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103(2):186\u201394. https:\/\/doi.org\/10.1159\/000443172.","journal-title":"Neuroendocrinology."},{"issue":"4","key":"14712_CR80","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/oncolo\/oyab039","volume":"27","author":"A Dasari","year":"2022","unstructured":"Dasari A, Shen C, Devabhaktuni A, Nighot R, Sorbye H. Survival according to primary tumor location, stage, and treatment patterns in locoregional gastroenteropancreatic high-grade neuroendocrine carcinomas. Oncologist. 2022;27(4):299\u2013306. https:\/\/doi.org\/10.1093\/oncolo\/oyab039.","journal-title":"Oncologist."},{"issue":"1","key":"14712_CR81","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1186\/s12885-020-07281-7","volume":"20","author":"J Chen","year":"2020","unstructured":"Chen J, Wang A, Ji K, Bu Z, Ji J. Comparison of overall survival of gastric neoplasms containing neuroendocrine carcinoma components with gastric adenocarcinoma: a propensity score matching study. BMC Cancer. 2020;20(1):777. https:\/\/doi.org\/10.1186\/s12885-020-07281-7.","journal-title":"BMC Cancer."},{"issue":"7","key":"14712_CR82","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.14180","volume":"4","author":"J Lin","year":"2021","unstructured":"Lin J, Zhao Y, Zhou Y, et al. Comparison of survival and patterns of recurrence in gastric neuroendocrine carcinoma, mixed adenoneuroendocrine carcinoma, and adenocarcinoma. JAMA Netw Open. 2021;4(7):e2114180. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.14180.","journal-title":"JAMA Netw Open."},{"issue":"8","key":"14712_CR83","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1007\/s00432-020-03214-w","volume":"146","author":"F Ma","year":"2020","unstructured":"Ma F, Wang B, Xue L, et al. Neoadjuvant chemotherapy improves the survival of patients with neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the stomach. J Cancer Res Clin Oncol. 2020;146(8):2135\u201342. https:\/\/doi.org\/10.1007\/s00432-020-03214-w.","journal-title":"J Cancer Res Clin Oncol."},{"key":"14712_CR84","doi-asserted-by":"crossref","unstructured":"Sorbye H, Grande E, Pavel M, et al. European neuroendocrine tumor society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. J Neuroendocrinol. 2023;35","DOI":"10.1111\/jne.13249"},{"issue":"7","key":"14712_CR85","doi-asserted-by":"publisher","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","volume":"19","author":"MH Shah","year":"2021","unstructured":"Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(7):839\u201368. https:\/\/doi.org\/10.6004\/jnccn.2021.0032.","journal-title":"J Natl Compr Canc Netw."},{"issue":"1","key":"14712_CR86","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3892\/mco.2020.2182","volume":"14","author":"B Ozdirik","year":"2021","unstructured":"Ozdirik B, Amthauer H, Schatka I, et al. A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: a case report. Mol Clin Oncol. 2021;14(1):20. https:\/\/doi.org\/10.3892\/mco.2020.2182.","journal-title":"Mol Clin Oncol."},{"issue":"8","key":"14712_CR87","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00259-006-0355-4","volume":"34","author":"M van Essen","year":"2007","unstructured":"van Essen M, Krenning EP, Bakker WH, de Herder WW, van Aken MO, Kwekkeboom DJ. Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging. 2007;34(8):1219\u201327. https:\/\/doi.org\/10.1007\/s00259-006-0355-4.","journal-title":"Eur J Nucl Med Mol Imaging."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14712-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-14712-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14712-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T19:08:36Z","timestamp":1706987316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-14712-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["14712"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-14712-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,7]]},"assertion":[{"value":"18 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number K12 CA237806 from the Emory K12 Clinical Oncology Training Program, awarded to MMS. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional support in part by the Contardi Research Fellowship and the Georgia CTSA UL1 Program (grant number UL1 TR002378). The acknowledged parties had no role in manuscript writing and decision to submit the manuscript for publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"DISCLOSURE"}}]}}